Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost versus timolol for early ocular hypertension after vitrectomy
ChiCTR1800014942Phase 4Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Mar 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of travoprost and timolol in ocular hypertension (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Intraocular pressure at Week 4. Started Mar 2018; status: recruiting.
02
Drugs
travoprosttimolol
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on ChiCTR1800014942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014942.